IN-111-OCTREOTIDE IMAGING IN PATIENTS WITH LONG-STANDING GRAVES OPHTHALMOPATHY

被引：19

作者：

BOHUSLAVIZKI, KH

OBERWOHRMANN, S

BRENNER, W

EBERHARDT, JU

MONIG, H

CLAUSEN, M

SIPPEL, C

WOLF, H

EPE, B

HENZE, E

机构：

[1] Clinics of Nuclear Medicine, Christian-Albrechts-Universitat Kiel, Kiel

[2] Clinics of Internal Medicine, Christian-Albrechts-Universitat Kiel, Kiel

来源：

NUCLEAR MEDICINE COMMUNICATIONS | 1995年 / 16卷 / 11期

关键词：

D O I：

10.1097/00006231-199511000-00006

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The aim of this study was to examine patients with long-standing Graves' ophthalmopathy using (111)Inoctreotide scintigraphy. Sixteen patients with inactive ophthalmopathy of up to 114 months duration and 14 normals were investigated for 48 h following an injection of 200 MBq In-111-octreotide. No significant tracer accumulation in the orbital region could be identified in any of the patients with long-standing Graves' ophthalmopathy. The orbit to brain (O/B) ratios after 24 and 48 h were 2.39 +/- 0.36 and 2.15 +/- 0.44 Versus 2.17 +/- 0.33 and 2.20 +/- 0.37 for the patients and normals, respectively (N.S.). In-111-octreotide accumulation in ophthalmopathy described in the literature may thus be a passing event limited to its active stage, which is consistent with the concept of imaging a lymphocytic infiltration. In this study, the lack of accumulation of In-111-octreotide in the orbital region during the inactive stage demonstrates an absence of somatostatin receptors in orbital tissue itself. Thus, in patients with inactive Graves' ophthalmopathy, there is no basis for a diagnostic approach with somatostatin.

引用

页码：912 / 916

页数：5

共 21 条

[1]

Krenning E.P., Breemann W., Kooij P., Lameris J.S., Bakker W.H., Koper J.W., Ausema L., Reubi J.C., Lamberts S., Localisation of endocrine-related tumors with radioiodina- ted analogue of somatostatin, Lancet, 333, pp. 242-244, (1989)

[2]

Lamberts S., Krenning E.P., Reubi J.C., The role of somatos-tatin and its analogs in the diagnosis and treatment of tumors, Endocrine Rev, 12, pp. 450-482, (1991)

[3]

Wagner H.N., Annual meeting highlights: Molecules with messages, J Nucl Med, 33, (1992)

[4]

Diaz M., Bockisch A., Kahaly G., Hahn K., Preliminary results of somatostatin-receptor-scintigraphy in endocrine oph-thalmopathy (Abstract), Eur J Nucl Med, 20, (1993)

[5]

Krenning E.P., Oei H.J., Kooji P., Wijngaarde R., Lamberts S., Wiersinga W.M., Prummel M.F., Royenvan E.A., Poub- Lon R., Hennemann G., Thyroid and orbital radioiodi- nated somatostatin (SS) accumulation (ACC) in Graves' disease (GD) and Graves' ophthalmopathy (GO) (abstract), J Nucl Med, 33, (1992)

[6]

Cordes M., Hosten N., Graf K.J., Wenzel K.W., Venz S., Keske U., Eichstadt H., Felix R., [111In]-DTPA-D-phenylalanine-octreotide SPECT for scintigraphic imaging of an enhanced somatostatin receptor density in endocrine ophthalmopathy, Fortschr Röntgenstr, 160, pp. 11-15, (1994)

[7]

Moncayo R., Dessl A., Judmaier W., Baldissera I., Kendler D., Watfah C., Sztankay A., Decristoforo C., Kackl M., Fridrich L., Riccabona G., Octreoscan and magnetic resonance imaging of endocrine orbitopathy (Abstract), Eur J Nucl Med, 21, (1994)

[8]

Postema P.T., Krenning E.P., Wijngaarde R., Kooy P.P., Oei H.Y., Van Den Bosch W.A., Reubi J.C., Wiersinga W.M., Hooijkaas H., Van Der Loos T., [123In-DTPA-D-Phe’]-octreotide scintigraphy in thyroidal and orbital Graves' disease: A parameter for disease activity?, J Clin Endocrinol Metab, 79, pp. 1845-1851, (1994)

[9]

Kahaly G., Diaz M., Beyer J., Bockisch A., Indium-111-pente- treotide scintigraphy in Graves' ophthalmopathy, J Nucl Med, 36, pp. 550-554, (1995)

[10]

Chang T.C., Kao S., Huang K.M., Octreotide and Graves' ophthalmopathy and pretibial myxoedema, Br Med J, 304, (1992)

← 1 2 3 →